International Business Machines said Thursday that it had joined forces with Moderna for a case study that evidenced quantum computing’s promise in medicine. While Moderna isn’t looking to replace ...

Moderna stock has faced heavy pressure from negative headlines, regulatory setbacks and political uncertainty. See why I ...

Shares of biotechnology company Moderna (NASDAQ:MRNA) fell 3.6% in the morning session after JPMorgan added the stock to its ...

DelveInsight's, “Melanoma Pipeline Insight” report provides comprehensive insights about 150+ companies and 170+ pipeline ...

Leerink Partners analyst Mani Foroohar maintained a Sell rating on Moderna on June 30. The company’s shares closed yesterday at $28.69. Foroohar covers the Healthcare sector, focusing on stocks such ...

Economic modeling is “very difficult” right now because “things are changing constantly,” Atlanta Fed President Raphael ...

Future Outlook and Challenges As Moderna looks to the future, several factors will be critical in determining its success.

Why Vaccine-Maker Moderna Is Injecting AI Across the Company More than 3,000 GPTs are reportedly in use at Moderna, which has partnered with OpenAI.

Moderna's cancer vaccine shows promise, but the company faces challenges with declining COVID demand and slow RSV uptake.

CEO Stéphane Bancel pointed to several key headwinds impacting Moderna’s outlook. One major factor is increasing competition in the COVID-19 vaccine market. Moderna’s share of the U.S. retail ...